1. Home
  2. AKTX vs IRD Comparison

AKTX vs IRD Comparison

Compare AKTX & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKTX
  • IRD
  • Stock Information
  • Founded
  • AKTX N/A
  • IRD 2018
  • Country
  • AKTX United States
  • IRD United States
  • Employees
  • AKTX N/A
  • IRD N/A
  • Industry
  • AKTX Biotechnology: Pharmaceutical Preparations
  • IRD
  • Sector
  • AKTX Health Care
  • IRD
  • Exchange
  • AKTX Nasdaq
  • IRD NYSE
  • Market Cap
  • AKTX 34.7M
  • IRD 36.1M
  • IPO Year
  • AKTX N/A
  • IRD N/A
  • Fundamental
  • Price
  • AKTX $1.24
  • IRD $1.15
  • Analyst Decision
  • AKTX
  • IRD Strong Buy
  • Analyst Count
  • AKTX 0
  • IRD 1
  • Target Price
  • AKTX N/A
  • IRD $8.00
  • AVG Volume (30 Days)
  • AKTX 26.3K
  • IRD 153.1K
  • Earning Date
  • AKTX 02-15-2025
  • IRD 02-19-2025
  • Dividend Yield
  • AKTX N/A
  • IRD N/A
  • EPS Growth
  • AKTX N/A
  • IRD N/A
  • EPS
  • AKTX N/A
  • IRD N/A
  • Revenue
  • AKTX N/A
  • IRD $8,381,000.00
  • Revenue This Year
  • AKTX N/A
  • IRD N/A
  • Revenue Next Year
  • AKTX N/A
  • IRD $29.37
  • P/E Ratio
  • AKTX N/A
  • IRD N/A
  • Revenue Growth
  • AKTX N/A
  • IRD N/A
  • 52 Week Low
  • AKTX $0.90
  • IRD $0.81
  • 52 Week High
  • AKTX $4.40
  • IRD $2.77
  • Technical
  • Relative Strength Index (RSI)
  • AKTX 51.97
  • IRD N/A
  • Support Level
  • AKTX $1.10
  • IRD N/A
  • Resistance Level
  • AKTX $1.39
  • IRD N/A
  • Average True Range (ATR)
  • AKTX 0.13
  • IRD 0.00
  • MACD
  • AKTX -0.00
  • IRD 0.00
  • Stochastic Oscillator
  • AKTX 61.54
  • IRD 0.00

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Share on Social Networks: